文献速递妇科

循环肿瘤细胞对卵巢癌预后价值的富集与检测方法:一项荟萃分析

Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
PubMed 文献 · Gynecol Oncol · 2021-03-03

结果显示CTC阳性与较差的总生存期(OS)和无进展生存期(PFS)显著相关,且治疗前CTC阳性、RT-PCR检测的CTC与更差OS相关。

要点

  • CTC阳性与卵巢癌患者较差OS(HR=1.77)和PFS(HR=1.53)显著相关。
  • 治疗前CTC阳性与较差OS显著相关(HR=1.79)。
  • RT-PCR检测的CTC与更差OS显著相关(HR=2.29)。

核心结论

  • 治疗前存在CTC提示更差的OS和PFS,CTC可能成为卵巢癌患者的预测生物标志物。
  • 采用RT-PCR检测的CTC似乎与卵巢癌患者更差的OS和PFS相关。

研究设计与样本

  • 系统评价与荟萃分析,检索Pubmed、Embase和Cochrane Library。
  • 直接提取或通过Engauge Digitizer v4.1从Kaplan-Meier生存曲线提取PFS和OS的HR及95%CI。
  • 按采样时间、治疗、富集方法和检测方法进行亚组分析。

主要发现

  • CTC与OS显著相关(HR=1.77,95%CI:1.42-2.21,p<0.00001)。
  • CTC与PFS显著相关(HR=1.53,95%CI:1.26-1.86,p<0.0001)。
  • 治疗前亚组CTC与OS显著相关(HR=1.79,95%CI:1.43-2.24,p<0.00001)。
  • 手术亚组CTC与OS显著相关(HR=1.82,95%CI:1.42-2.33,p<0.00001)。
  • RT-PCR亚组CTC与OS显著相关(HR=2.29,95%CI:1.53-3.42,p<0.0001)。

临床怎么用

  • 治疗前检测CTC可能有助于识别卵巢癌预后不良患者。
  • RT-PCR检测的CTC与更差OS相关,或可作为预后评估的检测方法参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recent studies have revealed that circulating tumor cells (CTCs) might predict bad prognosis, but the results were conflicting. Sampling time, treatment, enrichment method and detection method also varied. We aimed to evaluate whether patients with CTCs in peripheral blood have bad survival outcomes with consideration of the above four aspects. METHODS: Relevant studies were searched on Pubmed, Embase and the Cochrane Library. Studies of CTCs involving survival data available were identified for a systematic review and meta-analysis. HRs and 95% CIs for PFS and OS were extracted directly or from the Kaplan-Meier survival curves by the Engauge Digitizer v4.1. Subgroup analyses were performed to evaluate the effect of sampling time, treatment, enrichment method and detection method. RESULTS: Two clinical trials and thirteen retrospective studies with a total of 1285 patients were included. CTCs significantly correlated with OS (HR = 1.77, 95%CI:1.42-2.21, p < 0.00001 and PFS (HR = 1.53, 95%CI:1.26-1.86, p < 0.0001). Subgroup analyses showed that CTCs were significant associated with OS in the "Pre-therapy" subgroup (HR = 1.79, 95%CI:1.43-2.24, p < 0.00001), the "Surgery" group (HR = 1.82, 95%CI:1.42-2.33, p < 0.00001), and the "RT-PCR"subgroup (HR = 2.29, 95%CI:1.53-3.42, p < 0.0001). While for enrichment method, CTCs significantly correlated with OS in the"Physical method" subgroup (HR = 1.94, 95%CI:1.21-3.09, p = 0.006) and the "Immunological method" subgroup (HR = 1.84, 95%CI:1.37-2.48, p < 0.0001). CONCLUSIONS: The presence of CTCs prior to the treatment indicated worse OS and PFS and CTCs might be predictive biomarker for ovarian cancer patients . CTCs detected using RT-PCR seem to be associated with poorer OS and PFS in patients with ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Huang C, Lin X, He J, et al. Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis. Gynecol Oncol. 2021. PMID: 33674144. doi:10.1016/j.ygyno.2021.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。